Alternative Treatments for Tardive Dyskinesia When VMAT2 Inhibitors Are Unavailable
If Austedo (deutetrabenazine) and Ingrezza (valbenazine) are unavailable, the next treatment for tardive dyskinesia is to discontinue or reduce the dose of the offending antipsychotic medication if clinically feasible, or switch to a second-generation antipsychotic with lower D2 affinity such as clozapine or quetiapine. 1
Treatment Algorithm When VMAT2 Inhibitors Are Not Available
First-Line Alternative: Medication Adjustment
Step 1: Assess Clinical Feasibility of Antipsychotic Withdrawal
- If the patient's psychiatric condition is stable and the underlying disorder permits, gradually withdraw the causative antipsychotic medication 2
- This is the most effective intervention when possible, as TD is directly caused by dopamine receptor antagonism
- Monitor closely for psychiatric decompensation during withdrawal
Step 2: If Antipsychotic Continuation Is Necessary
- Switch from first-generation (typical) antipsychotics to second-generation (atypical) antipsychotics with lower D2 receptor affinity 2
- Preferred agents: Clozapine or quetiapine are the best options due to their significantly lower D2 binding affinity 2
- These switches may reduce TD symptoms while maintaining psychiatric stability
Step 3: Dose Reduction Strategy
- If switching is not feasible, reduce the antipsychotic dose to the minimum effective level while remaining within the therapeutic range 2, 3
- This approach balances TD management with psychiatric symptom control
Management of Concurrent Extrapyramidal Symptoms
The APA guidelines 1 provide specific recommendations for other antipsychotic-induced movement disorders that may coexist with TD:
For Acute Dystonia:
- Treat with anticholinergic medication 1
For Drug-Induced Parkinsonism:
- Lower the antipsychotic dose, OR
- Switch to another antipsychotic, OR
- Add anticholinergic medication 1
For Akathisia:
- Lower the antipsychotic dose, OR
- Switch to another antipsychotic, OR
- Add a benzodiazepine, OR
- Add a beta-adrenergic blocking agent 1
Critical Clinical Considerations
Why VMAT2 Inhibitors Are First-Line
The APA guideline 1 explicitly recommends VMAT2 inhibitors (deutetrabenazine and valbenazine) as first-line treatment for moderate to severe or disabling tardive dyskinesia. Both medications demonstrated significant improvements in AIMS scores in controlled trials 4, 5, with deutetrabenazine showing a treatment effect of -2.5 units (p<0.0001) and valbenazine showing statistically significant improvements at 80mg dosing.
The Reality of Limited Alternatives
The evidence base for TD treatment beyond VMAT2 inhibitors is notably weaker 2. The Canadian guidelines acknowledge that "data on tardive dyskinesia treatment are limited, and the best management strategy remains prevention" 2. This underscores why accessing VMAT2 inhibitors should be prioritized whenever possible.
Common Pitfalls to Avoid
- Do not add anticholinergic medications for TD itself - Unlike other extrapyramidal symptoms, anticholinergics are not indicated for tardive dyskinesia and may worsen symptoms
- Avoid increasing antipsychotic doses - This may temporarily mask TD but worsens the underlying pathology
- Do not abruptly discontinue antipsychotics - Gradual tapering is essential to prevent withdrawal-emergent dyskinesia and psychiatric relapse
- Monitor for withdrawal-emergent TD - Symptoms may temporarily worsen when reducing or stopping antipsychotics before improving 5
Prevention Remains Paramount
Since treatment options are limited without VMAT2 inhibitors, prevention is critical 2:
- Prescribe antipsychotics only for specific indications
- Use the minimum effective dose
- Minimize duration of therapy
- Consider second-generation antipsychotics over first-generation when appropriate
Long-Term Perspective
If VMAT2 inhibitors become available later, they should be initiated promptly for moderate to severe TD, as studies show 97% of patients completing 48 weeks of valbenazine treatment achieved clinically meaningful improvement 6.